Keratin compositions for treatment of bone deficiency or injury
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/17
A61K-038/18
A61K-035/28
A61K-038/39
A61L-027/22
A61L-027/44
A61L-027/54
A61K-045/06
출원번호
US-0895485
(2013-05-16)
등록번호
US-9220754
(2015-12-29)
발명자
/ 주소
Van Dyke, Mark E.
Teli, Thaleia
출원인 / 주소
Wake Forest University Health Sciences
대리인 / 주소
Myers Bigel Sibley & Sajovec, P.A.
인용정보
피인용 횟수 :
0인용 특허 :
53
초록▼
A bone graft composition is described, with one or more of: (a) keratose; (b) kerateine; (c) optionally, particulate filler; (d) optionally, an antibiotic; and (e) water or saline. The composition may be provided in sterile form in a container, and optionally lyophilized. Methods of treating a bone
A bone graft composition is described, with one or more of: (a) keratose; (b) kerateine; (c) optionally, particulate filler; (d) optionally, an antibiotic; and (e) water or saline. The composition may be provided in sterile form in a container, and optionally lyophilized. Methods of treating a bone deficiency or fracture making use of such compositions are also described.
대표청구항▼
1. A bone graft composition, comprising: (a) from 1 to 90 percent by weight keratose;(b) from 1 to 90 percent by weight kerateine;(c) from 0.001 to 5 percent by weight bone morphogenetic protein 2 (BMP2);(d) optionally, from 1 to 90 percent by weight particulate filler;(e) optionally, from 0.001 to
1. A bone graft composition, comprising: (a) from 1 to 90 percent by weight keratose;(b) from 1 to 90 percent by weight kerateine;(c) from 0.001 to 5 percent by weight bone morphogenetic protein 2 (BMP2);(d) optionally, from 1 to 90 percent by weight particulate filler;(e) optionally, from 0.001 to 5 percent by weight antibiotic; and(f) water or saline to balance. 2. The composition of claim 1, wherein said composition is a nonwoven mesh, sponge, or hydrogel. 3. The composition of claim 1, wherein said composition is sterile. 4. The composition of claim 3 packaged in a sterile container. 5. The composition of claim 1, wherein said keratose is alpha/KAP keratose, gamma keratose, or mixtures thereof. 6. The composition of claim 1, wherein said kerateine is alpha/KAP kerateine, gamma kerateine, or mixtures thereof. 7. The composition of claim 1, wherein said composition comprises from 10 to 90 percent by weight keratose and from 90 to 10 percent by weight kerateine. 8. The composition of claim 1, wherein said composition comprises from 1 to 30 percent by weight keratose and from 1 to 30 percent by weight kerateine. 9. A lyophilized or freeze-dried composition which upon reconstitution with water or saline solution produces a bone graft material composition, comprising: (a) from 1 to 90 percent by weight keratose;(b) from 1 to 90 percent by weight kerateine;(c) from 0.001 to 5 percent by weight bone morphogenetic protein 2 (BMP2);(d) optionally, from 1 to 90 percent by weight particulate filler;(e) optionally, from 0.001 to 5 percent by weight antibiotic; and(f) water or saline to balance. 10. A bone graft composition, comprising: (a) from 1 to 90 percent by weight keratose;(b) from 1 to 90 percent by weight kerateine;(c) from 1 to 90 percent by weight particulate filler;(d) optionally, from 0.001 to 5 percent by weight antibiotic; and(e) water or saline to balance,wherein said particulate filler is selected from the group consisting of tetracalcium phosphate, tricalcium phosphate, calcium alkali phosphate ceramic, bioglass, calcium carbonate, calcium hydroxide, calcium oxide, calcium fluoride, calcium sulfate, magnesium hydroxide, hydroxyapatite, calcium phosphorus apatite, magnesium oxide, magnesium carbonate, magnesium fluoride, collagen, and mixtures thereof. 11. The composition of claim 10, wherein said particulate filler is selected from the group consisting of hydroxyapatite, tricalcium phosphate, and mixtures thereof. 12. The composition of claim 10, wherein said composition comprises an antibiotic selected from the group consisting of cefazolin, vancomycin, gentamycin, erythromycin, bacitracin, neomycin, penicillin, polymycin B, tetracycline, biomycin, chloromycetin, streptomycin, ampicillin, azactam, tobramycin, clindamycin, gentamicin, and combinations thereof. 13. A bone graft composition, comprising: (a) from 1 to 90 percent by weight keratose;(b) from 1 to 90 percent by weight kerateine;(c) optionally, from 1 to 90 percent by weight particulate filler;(d) optionally, from 0.001 to 5 percent by weight antibiotic; and(e) water or saline to balance, andfurther comprising stem cells. 14. The composition of claim 13, wherein said stem cells are mesenchymal stem cells. 15. The composition of claim 14, wherein said mesenchymal stem cells are harvested from bone marrow or adipose tissue. 16. The composition of claim 13, wherein said stem cells are adipose derived stem cells. 17. The composition of claim 13, wherein said stem cells are collected from a human subject who is at least 40 years old at the time of harvest. 18. A method of treating a bone deficiency in a subject in need thereof, comprising administering to said subject in a treatment effective amount a bone graft composition, comprising: (a) from 1 to 90 percent by weight keratose;(b) from 1 to 90 percent by weight kerateine;(c) optionally, from 1 to 90 percent by weight particulate filler;(d) optionally, from 0.001 to 5 percent by weight antibiotic; and(e) water or saline to balance. 19. The method of claim 18, wherein said subject is an osteoporotic or osteopenic subject. 20. The method of claim 18, wherein said administering comprises injecting. 21. The method of claim 18, wherein the bone graft composition further comprises autologous stem cells. 22. The method of claim 21, wherein said stem cells are mesenchymal stem cells. 23. The method of claim 22, wherein said mesenchymal stem cells are harvested from bone marrow or adipose tissue. 24. The method of claim 21, wherein said stem cells are adipose derived stem cells. 25. The method of claim 21, wherein said stem cells are collected from a human subject who is at least 40 years old at the time of harvest. 26. A method of treating a fracture in a subject in need thereof, comprising contacting to said fracture in a treatment-effective amount a bone graft composition, comprising: (a) from 1 to 90 percent by weight keratose;(b) from 1 to 90 percent by weight kerateine;(c) optionally, from 1 to 90 percent by weight particulate filler;(d) optionally, from 0.001 to 5 percent by weight antibiotic; and(e) water or saline to balance. 27. The method of claim 26, wherein said composition further comprises from 0.001 to 5 percent by weight bone morphogenetic protein 2 (BMP2). 28. The method of claim 26, wherein said composition comprises a particulate filler selected from the group consisting of tetracalcium phosphate, tricalcium phosphate, calcium alkali phosphate ceramic, bioglass, calcium carbonate, calcium hydroxide, calcium oxide, calcium fluoride, calcium sulfate, magnesium hydroxide, hydroxyapatite, calcium phosphorus apatite, magnesium oxide, magnesium carbonate, magnesium fluoride, collagen, and mixtures thereof. 29. The method of claim 26, wherein said composition comprises a particulate filler selected from the group consisting of hydroxyapatite, tricalcium phosphate, and mixtures thereof. 30. The method of claim 26, wherein said composition comprises an antibiotic selected from the group consisting of cefazolin, vancomycin, gentamycin, erythromycin, bacitracin, neomycin, penicillin, polymycin B, tetracycline, biomycin, chloromycetin, streptomycin, ampicillin, azactam, tobramycin, clindamycin, gentamicin, and combinations thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (53)
Van Dyke Mark E. ; Timmons Scott F. ; Blanchard Cheryl R. ; Siller-Jackson Arlene J. ; Smith Robert A., Absorbent keratin wound dressing.
Song Dong Hyuk,KRX ; Choi Yeong Jin,KRX ; Kim Kil Joong,KRX ; Lee Young Chul,KRX, Amino acid silicon polymer, method for preparing the same, cosmetic particles surface-treated with the same, and cosmetic composition containing the particles.
Pernia Luis R. (350 39th St. Northport AL 35476) Kaakedjian Garbis (Av. Andres BE1/0 ; Sector Las Palmas ; Edif Rubi Apt. 10-A Caracas VEX), Biological filler and use of same.
Smestad Thomas L. (Palo Alto CA) Prows Daniel (Santa Clara CA) Chu George H. (Sunnyvale CA) Hendricks Diana M. (Brea CA), Gamma irradiation of collagen/mineral mixtures.
Mark E. Van Dyke ; Cheryl R. Blanchard ; Scott F. Timmons ; Arlene J. Siller-Jackson ; Robert A. Smith, Implantable prosthetic or tissue expanding device.
Siller-Jackson, Arlene J.; Van Dyke, Mark E.; Timmons, Scott F.; Blanchard, Cheryl R.; Smith, Robert A., Keratin-based powders and hydrogel for pharmaceutical applications.
Smith Robert A. (2246 E. Northside Dr. Jackson MS 39211) Blanchard Cheryl R. (San Antonio TX) Lankford ; Jr. James (San Antonio TX), Nonantigenic keratinous protein material.
Van Dyke Mark E. ; Timmons Scott F. ; Blanchard Cheryl R. ; Siller-Jackson Arlene J. ; Smith Robert A., Nonwoven sheet and film containing water absorbent keratin.
Peplow, Philip Victor; Dias, Subasinghe Nisanke George Premalal Jayantha; Roddick-Lanzilotta, Alisa Dawn; Kelly, Robert James, Orthopaedic materials derived from keratin.
Brod Joel (Paris FRX) Kermici Michel (Paris FRX), Pharmaceutical composition for treatment and/or prevention of diseases of the skin involving an inflammatory process.
Read Marjorie S. (Durham NC) Reddick Robert L. (Durham NC) Bode Arthur P. (Greenville NC), Pharmaceutically acceptable fixed-dried human blood platelets.
Cohen Arthur I. (Rochester NY) Sim James S. Y. (Rochester NY) Van Horn Maurice H. (Rochester NY) Gordesky Stanley E. (Rochester NY) Gordon Stanley I. (Rochester NY), Sustained release pharmaceutical composition.
Van Dyke Mark E. ; Blanchard Cheryl R. ; Timmons Scott F. ; Siller-Jackson Arlene J. ; Smith Robert A., Water absorbent keratin and gel formed therefrom.
Piez Karl A. (Menlo Park CA) Pharriss Bruce B. (Palo Alto CA) Chu George H. (Sunnyvale CA) Smestad Thomas L. (Palo Alto CA) Hendricks Diana (Palo Alto CA), Xenogeneic collagen/mineral preparations in bone repair.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.